{
  "id": "601c13be1cb411341a00000d",
  "type": "summary",
  "question": "Describe the mechanism of action of Omecamtiv Mecarbil.",
  "ideal_answer": "Omecamtiv mecarbil is a novel, selective cardiac myosin activator that has been shown to improve cardiac function and to decrease ventricular volumes, heart rate, and N-terminal pro-B-type natriuretic peptide in patients with heart failure.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/21415352",
    "http://www.ncbi.nlm.nih.gov/pubmed/33165138",
    "http://www.ncbi.nlm.nih.gov/pubmed/33176437",
    "http://www.ncbi.nlm.nih.gov/pubmed/32969560",
    "http://www.ncbi.nlm.nih.gov/pubmed/26140433",
    "http://www.ncbi.nlm.nih.gov/pubmed/26587768",
    "http://www.ncbi.nlm.nih.gov/pubmed/32035892",
    "http://www.ncbi.nlm.nih.gov/pubmed/33185990",
    "http://www.ncbi.nlm.nih.gov/pubmed/31267148",
    "http://www.ncbi.nlm.nih.gov/pubmed/27322915",
    "http://www.ncbi.nlm.nih.gov/pubmed/29707029",
    "http://www.ncbi.nlm.nih.gov/pubmed/26709596",
    "http://www.ncbi.nlm.nih.gov/pubmed/21856481",
    "http://www.ncbi.nlm.nih.gov/pubmed/21856480",
    "http://www.ncbi.nlm.nih.gov/pubmed/29792814",
    "http://www.ncbi.nlm.nih.gov/pubmed/29278207",
    "http://www.ncbi.nlm.nih.gov/pubmed/32513536",
    "http://www.ncbi.nlm.nih.gov/pubmed/26065842",
    "http://www.ncbi.nlm.nih.gov/pubmed/32636378",
    "http://www.ncbi.nlm.nih.gov/pubmed/26025342",
    "http://www.ncbi.nlm.nih.gov/pubmed/28082673",
    "http://www.ncbi.nlm.nih.gov/pubmed/28775348",
    "http://www.ncbi.nlm.nih.gov/pubmed/31103235",
    "http://www.ncbi.nlm.nih.gov/pubmed/25680381"
  ],
  "snippets": [
    {
      "text": "Omecamtiv mecarbil is a novel, selective cardiac myosin activator that has been shown to improve cardiac function and to decrease ventricular volumes, heart rate, and N-terminal pro-B-type natriuretic peptide in patients with chronic HF.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32035892",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Omecamtiv mecarbil (OM), an activator of cardiac myosin, strongly affects contractile characteristics of the ventricles and, to a much lesser extent, the characteristics of atrial contraction. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32513536",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Omecamtiv mecarbil (OM) is a putative positive inotropic tool for treatment of systolic heart dysfunction, based on the finding that in vivo it increases the ejection fraction and in vitro it prolongs the actin-bond life time of the cardiac and slow-skeletal muscle isoforms of myosin. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32636378",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two novel cardiac myotropes, omecamtiv mecarbil and danicamtiv, target cardiac myosin to increase left ventricular systolic performance.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33165138",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Omecamtiv mecarbil, a novel activator of cardiac myosin, improves left ventricular systolic function and remodeling and reduces natriuretic peptides.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33176437",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33185990",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33185990",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The mechanism of action of omecamtiv mecarbil also provides insights into uncovering how force is generated by molecular motors.Omecamtiv mecarbil (OM) is a cardiac myosin activator that is currently in clinical trials for heart failure treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28775348",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Omecamtiv mecarbil is a selective, small-molecule activator of cardiac myosin that is being developed as a potential treatment for heart failure with reduced ejection fraction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28775348",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The myosin activator omecamtiv mecarbil: a promising new inotropic agent.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27322915",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A novel myosin activator, omecamtiv mecarbil (OM), is a cardiac inotropic agent with a unique new mechanism of action, which is thought to arise from an increase in the transition rate of myosin into the actin-bound force-generating state without increasing calcium (Ca2+) transient. There remains, howeve",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31267148",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The energy-saving effect of a new myosin activator, omecamtiv mecarbil, on LV mechanoenergetics in rat hearts with blood-perfused isovolumic contraction model.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31267148",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Omecamtiv mecarbil (OM) is a selective cardiac myosin activator (myotrope), currently in Phase 3 clinical investigation as a novel treatment for heart failure with reduced ejection fraction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32969560",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28775348",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "OBJECTIVE: Omecamtiv mecarbil is a novel small molecule that directly activates cardiac myosin and increases cardiac contractility without increasing cardiac myocyte intracellu",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26709596",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Omecamtiv mecarbil (OM) is a cardiac myosin activator that is currently in clinical trials for heart failure treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28775348",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A novel myosin activator, omecamtiv mecarbil (OM), is a cardiac inotropic agent with a unique new mechanism of action, which is thought to arise from an increase in the transition rate of myosin into the actin-bound force-generating state without increasing calcium (Ca2+) transient.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31267148",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: Omecamtiv mecarbil is a novel small molecule that directly activates cardiac myosin and increases cardiac contractility without increasing cardiac myocyte intracellul",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26709596",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Omecamtiv mecarbil (OM) is a compound that has been developed to treat systolic heart failure via targeting the cardiac myosin heavy chain to increase myocardial contractility.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31103235",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Omecamtiv mecarbil is a first-in-class cardiac myosin activator, which increases the proportion of myosin heads that are tightly bound to actin and creates a force-producing state that is not associated with cytosolic calcium accumulation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29707029",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "nd mortality. A novel selective cardiac myosin activator, omecamtiv mecarbil (CK-1827452/ AMG-423) is a small molecule that activates the sarcomere proteins directly, resulting in prolonged systolic ejection time and increased cardiac ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26587768",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26140433",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "This study tested the hypothesis that omecamtiv mecarbil, a selective cardiac myosin activator, will augment cardiac function in human beings.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21856480",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The small molecule drug omecamtiv mecarbil (OM) specifically targets cardiac muscle myosin and is known to enhance cardiac muscle performance, yet its impact on human cardiac myosin motor function is unclear.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28082673",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Omecamtiv Mecarbil: A Myosin Motor Activator Agent with Promising Clinical Performance and New in vitro Results.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29278207",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26587768",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Omecamtiv Mecarbil, a Cardiac Myosin Activator, Increases Ca2+ Sensitivity in Myofilaments With a Dilated Cardiomyopathy Mutant Tropomyosin E54K.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26065842",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A novel class of agents, the myosin motor activators, acts directly on cardiac myosin resulting in an increased force generation and prolongation of contraction. Omecamtiv mecarbil, the lead molecule of this group, is now in human phase 3 displaying promising clinical performance.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29792814",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We determined the effect of Omecamtiv Mecarbil, a novel allosteric effector of cardiac muscle myosin, on the kinetic and \"in vitro\" motility properties of the porcine ventricular heavy meromyosin (PV-HMM). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25680381",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21856481",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We report the first study of the cardiac myosin activator, omecamtiv mecarbil, in patients with systolic heart failure.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21856481",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To avoid these limitations, we previously developed omecamtiv mecarbil, a small-molecule, direct activator of cardiac myosin. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21415352",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26025342",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Omecamtiv mecarbil (OM) is a novel inotropic agent that prolongs systolic ejection time and increases ejection fraction through myosin ATPase activation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26025342",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}